Overview
The purpose of this study is to evaluate the efficacy and safety of Oncolytic Adenovirus(H101) combined with PD-1 inhibitor in patients with advanced malignant pleural mesothelioma who have previously been resistant to advanced PD-1 inhibitors.
Description
By monitoring the clinical symptoms of patients with advanced immune resistant pleural mesothelioma treated with adenovirus injection combined with programmed death receptor (PD-1) inhibitors, we analyze and explore the effectiveness and safety of using oncolytic virus drugs. Exploring the influencing factors of using oncolytic adenovirus injection combined with PD-1 inhibitors to reverse immune resistance in MPM patients. Evaluate the safety of the drug, and finally evaluate the quality of life of patients using oncolytic adenovirus injection(H101) combined with PD-1 inhibitors.
Eligibility
Inclusion Criteria:
- Age 18-75 years old (including boundary values), regardless of gender.
- Confirmed as late stage MPM patients who have failed immunotherapy.
- The patient or their legal representative can understand and sign the informed consent form.
- At least one lesion that can safely undergo intratumoral injection or intrapleural injection of oncolytic adenovirus as the target lesion, with a diameter of spiral CT ≥ 1cm or ordinary CT ≥ 2cm, and can be measured through imaging methods.
- ECOG score 0-2.
Exclusion Criteria:
- Physicians participating in the study believe that patients may not be able to provide continuous follow-up information.
- Any uncontrollable clinical problems (such as severe mental, neurological, cardiovascular, respiratory, and other systemic diseases).
- Contraindications to relevant drugs (such as oncolytic adenoviruses, PD-1 inhibitors, etc.)